Provided by Tiger Trade Technology Pte. Ltd.

Eupraxia Pharmaceuticals

8.64
+0.52006.40%
Volume:90.77K
Turnover:766.14K
Market Cap:437.60M
PE:-9.82
High:8.66
Open:8.13
Low:8.13
Close:8.12
52wk High:9.32
52wk Low:2.68
Shares:50.65M
Float Shares:39.63M
Volume Ratio:2.93
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8798
EPS(LYR):-0.7642
ROE:-61.02%
ROA:-36.21%
PB:7.50
PE(LYR):-11.31

Loading ...

Eupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact

TIPRANKS
·
3 hours ago

Eupraxia Pharmaceuticals Prices $55 Million Public Offering

MT Newswires Live
·
18 hours ago

Eupraxia Pharmaceuticals 6.4M share Spot Secondary priced at $7.00

TIPRANKS
·
Yesterday

Eupraxia Pharmaceuticals announces common shares offering, no amount given

TIPRANKS
·
Yesterday

Eupraxia Pharmaceuticals Announces Proposed Public Offering

GlobeNewswire
·
Yesterday

Eupraxia Pharmaceuticals management to meet with Cantor

TIPRANKS
·
Feb 03

Eupraxia Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Jan 15

Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald

TIPRANKS
·
Jan 15

H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)

TIPRANKS
·
Jan 09

Eupraxia Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 09

Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus

Benzinga_recent_news
·
Jan 09

Eupraxia Pharmaceuticals Up Nearly 16%, on Pace for Largest Percent Increase Since November 2024 -- Data Talk

Dow Jones
·
Nov 11, 2025

Eupraxia Pharmaceuticals Q3 EPS $(0.19) Beats $(0.21) Estimate

Benzinga
·
Nov 05, 2025

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 05, 2025

Eupraxia Pharmaceuticals Releases Q3 2025 Financial Results

TIPRANKS
·
Nov 05, 2025

Eupraxia Pharmaceuticals Advances EoE Treatment with EP-104GI Trial

TIPRANKS
·
Oct 28, 2025

Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion

TIPRANKS
·
Oct 01, 2025

Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

TIPRANKS
·
Sep 30, 2025

Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering

TIPRANKS
·
Sep 30, 2025

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

GlobeNewswire
·
Sep 30, 2025